On Feb. 8, 2023, BD announced that it had received Emergency Use Authorization from the U.S. Food and…
On Feb. 7, 2023, an NIH funded study by University of North Carolina reported that Bivalent booster vaccines…
On Jan. 26, 2023, the U.S. Food and Drug Administration revised the Emergency Use Authorization for Evusheld (tixagevimab…
On Jan. 10, 2023, the U.S. National Institutes of Health (NIH) reported that antiviral treatments can help reduce…
On Dec. 8, 2022, Moderna announced it had received emergency use authorization from the U.S. Food and Drug…
On Dec. 7, 2022, Novavax announced that Health Canada had approved a supplement to a New Drug Submission…
On Dec. 5, 2022, Pfizer and BioNTech announced that the companies had submitted an application to the U.S….
On Nov. 29, 2022, Novavax announced that the World Health Organization had issued an updated Emergency Use Listing…
On Nov. 18, 2022, Novavax announced that Health Canada had granted expanded authorization for Nuvaxovid (COVID-19 Vaccine (Recombinant…
On Nov. 16, 2022, Pfizer and BioNTech announced that the companies had initiated a Phase 1 study to…
On Nov. 9, 2022, Novavax announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United…
On Nov. 8, 2022, Novavax announced topline results from its Phase 3 Boosting Trial for the SARS-CoV-2 rS…
On Nov. 3, 2022, Health Canada authorized an adapted version of the Moderna Spikevax COVID-19 vaccine that targets…
On Nov. 2, 2022, Hologic announced that it had been awarded a $19 million contract from the Biomedical…
On Nov. 1, 2022, the U.S. Department of Agriculture’s (USDA) Animal and Plant Health Inspection Service (APHIS) announced…
On Oct. 25, 2022, the University of Washington reported that daily global COVID-19 infections were projected to rise…
On Oct. 25, 2022, Pacific Northwest National Laboratory (PNNL) announced that scientists have shown that they can detect…
On Oct. 19, 2022, Novavax announced that the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) has received emergency use authorization…
On Oct. 19, 2022, Moderna announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human…
On Oct. 17, 2022, Moderna and Gavi, the Vaccine Alliance, a biotechnology company pioneering messenger RNA (mRNA) therapeutics…
On Oct. 13, 2022, researchers from the University of Oxford reported findings from a study exploring how certain…
On Oct. 13, 2022, Novavax announced positive results from the Phase 1/2 clinical trial of its COVID-19-Influenza Combination…
On Oct. 12, 2022, Moderna announced that it had received emergency use authorization from the U.S. Food and…
On Oct. 12, 2022, Pfizer and BioNTech announced that the U.S. Food and Drug Administration granted Emergency Use…
On Oct. 11, 2022, Roche announced the launch of its next-generation portfolio SARS-CoV-2 rapid antigen tests (“2.0”) for…
On Oct. 11, 2022, researchers from the University of Oxford have reported new findings from a Phase 1…
On Oct. 10, 2022, Novavax announced that partner, SK bioscience, had submitted a Post Approval Change Application to…
On Oct. 10, 2022, Novavax announced that Switzerland’s Federal Office of Public Health had recommended Nuvaxovid (NVX-CoV2373) as…
On Oct. 6, 2022, Merck and Ridgeback Biotherapeutics issued the following announcement regarding data from two real-world evidence…
On Oct. 4, 2022, Washington University in St. Louis announced it had licensed the rights to develop, manufacture…